ABSTRACTS

P2.01 Evaluation of the Red Blood Cell Advanced Software Application on the CellaVision DM96

M. Criel, M. Godefroid, B. Deckers, H. Devos, B. Cauwelier, J. Emmerechts

P2.09 Prekallikrein deficiency in a 15-year-old boy with Ménière’s disease: a case report

M. Criel, F. Declau, C. Schuermans, K. Ver Elst, S. Vermeiren, S. Weekx, J. Lemmens

P2.08 EBV associated hemophagocytic lymphohistiocytosis: a common infection running a life-threatening course

K. Saevels, K. Clotman, A. Verlinden

P2.07 Characterization of a novel innate CD8+ T cell lineage generated in human thymus

G. Verstichel, G. Goetgeluk, L. Martens, T. Taghon, G. Leclercq, T. Kerre, Y. Saeys, B. Vandekerckhove

P2.06 Salt but not glucocorticosteroïds enhances Th17 differentiation from naïve T cells in vitro

L. Delens, S. Servais, L. Vrancken, G. Ehx, G. Fransolet, M. Hannon, S. Dubois, C. Daulne, Y. Beguin, F. Baron

P2.05 Intravenous immunoglobulins as a preventive treatment of maternofoetal platelet alloimmunisation

A. Theis, C. Crespo Sanchez, L. Plawny

P2.04 Application of a clot based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates

B. Devalet, A. Wannez, N. Bailly, L. Alpan, D. Gheldof, J. Douxfils, V. Deneys, B. Bihin, B. Chatelain, J-M. Dogné, C. Chatelain, F. Mullier

P2.03 Evaluation of the Red Blood Cell Advanced Software Application on the CellaVision DM96

M. Criel, M. Godefroid, B. Deckers, H. Devos, B. Cauwelier, J. Emmerechts

P2.02 Belgian consensus on the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria

B. Devalet, N. Boeckx, B. Chatelain, C. Chatelain, D. Deeren, A. Gothot, S. Meers, T. Devos

P2.10 Role of Extracellular Vesicles for Thrombosis in Paroxysmal Nocturnal Hemoglobinuria patients

W. Wannez, C. Bouvy, B. Devalet, F. Mullier, B. Chatelain, C. Chatelain, J-M. Dogné

P1.16 Cutaneous involvement and linear IgA dermatosis in a patient with angioimmunoblastic T-cell lymphoma

A. Camboni, C. Dachelet, E. Van den Neste, L. Sacre, L. Marot

P1.15 Multiple Myeloma in Black Africans, clinical and biological characteristics

N. Grailet, C. Ninane, N. Van Langendonck, C. Hermans, D. Latinne, L. Michaux, M.C. Vekemans

P1.14 Molecular biology vs. Statistics: A patient with concomitantly occurring CLL and MPN

B. Heyrman, A. De Becker, R. Schots

P1.13 Blocking S100A9 interactions in the Multiple Myeloma bone marrow environment reduces angiogenesis and tumor growth

E. Van Valckenborgh, K. De Veirman, H. De Raeve, K. Maes, E. De Bruyne, E. Menu, K. Vanderkerken

P1.12 Identification of clinical and biological parameters predictive of chemotherapy completion and two-year overall survival in clinically fit older patients with haematological malignancies

S. Dubruille, Y. Libert, M. Roos, S. Vandenbossche, A. Collard, N. Meuleman, M. Maerevoet, A. Etienne, C. Reynaert, D. Razavi, D. Bron

P1.11 Retrospective Chart Review of Hospitalisations and Costs Associated with the Treatment of Adults with Philadelphia-negative (-) B-precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) in Belgium

C. Graux, D. Strens, C. Hoefkens, B. Barber, Z. Cong

P1.10 Immunoglobulin and T-cell receptor gene analysis by next-generation sequencing

J. Van Der Straeten, B. Caljon, C. Demanet, M.H.C. Bakkus

P4.04 Role of extracellular vesicles on multidrug resistance transfer between leukemia cells

C. Bouvy, A. Wannez, C. Chatelain, J-M. Dogné

P4.12 Case Report: A woman with pancytopenia, polyuria and polydipsia

I. De haes, D. Schepens, I. Vande Broek

P4.11 Unusual cutaneous paraneoplastic syndrome in the setting of acute myeloid leukemia

T. Tamakloe, N. Meité, S. Amat, P. Janssens, L. Marot, J-P. Defour, P. Saussoy, H. Poirel, L. Michaux, E. Van den Neste, L. Knoops, V. Havelange, C. Lambert, X. Poiré, M.C. Vekemans

P4.10 The Ponatinib Named Patient Programme (NPP): Real-life Data from Belgian Patients

L. Knoops, G. Verhoef, Z. Berneman, D. Selleslag, N. Straetmans, L. Noens, P. Lewalle, M. André, D. Pranger, P. Zachée, E. Strobbe, L.J. McGarry, T. Devos

P4.09 MPL S204P is a Recurrent Mutation in Essential Thrombocythemia

C. AL Assaf, P. Papadopoulos, S. Smits, L. Gutiérrez, I. Tanyalcin, M. Fierce, E. Lierman, T. Devos, J. Billiet, P. Vandenberghe

P4.08 Two cases of atypical CALR mutations in MPN patients

C. Sagot, H. Charlier, B. Koopmansch, F. Lambert

P4.07 Identification of a TPM3-PDGFRB fusion transcript and its chromosomal breakpoints by RNA-Seq in a case of Chronic Eosinophilic Leukemia

B. Koopmansch, M. Lopez y Cadenas, B. Hennuy, F. Lambert

P4.06 Cost minimization analysis of a home administration program in Belgium

D. Selleslag, S. De Ruysscher, J. Patris, S. Vermeersch, J. Verstraete, P. Persyn, K. Herman, H. van Loon, L. Annemans

P4.05 Utility of next-generation sequencing in clinical practice: 5 cases diagnosed with primary myelofibrosis

N. Put, B. Maes, R. Achten, K. Deraedt, K. Theunissen, V. Madoe

P1.09 RASSF4 functions as a tumor suppressor in Multiple Myeloma

E. De Smedt, K. Maes, S. Verhulst, C. Heirman, A. Maes, K. Breckpot, L. Van Grunsven, J. Moreaux, E. De Bruyne

P4.03 Comparison of GeneXpert BCR-ABL Monitor and GeneXpert BCR-ABL Ultra assay for the quantification of BCR-ABL1 in CML patients under TKI treatment

H. Claerhout, J. De Roover, K. Bruyninckx, N. Boeckx

P4.02 BCR-ABL1 kinase domain mutation analysis by next generation sequencing: comparison of Ion Torrent PGM and MiSeq platforms

F. Nollet, P. Vannuffel, C. De Rop, S. Vermeire, D. David, B. Cauwelier

P4.01 Myelodysplastic syndromes : a preliminary assessment of flow cytometric scores in clinical practice

R. Harkati

P3.04 Epidemiology of patients receiving hematopoietic stem cell patients in Belgium

P. Chevalier, E. Tsakeu, M. Lamotte

P3.03 Anemia, thrombocytopenia and radiculitis in the setting of allogeneic stem cell transplantation

S. Amat, T. Tamakloe, N. Meité, V. Havelange, M.C. Vekemans, C. Lambert, E. Van den Neste, X. Poiré

P3.02 Ponatinib as bridge to haematopoietic stem cell transplantation in a patient with a myeloid/lymphoid neoplasm with eosinophilia and abnormality of FGFR1: a case report

H. Maes, J. Maertens, S. Smits, E. Lierman, N. Boeckx, T. Tousseyn, G. Verhoef, P. Vandenberghe

P3.01 NGS based HLA-genotyping using 2 reagent kits (Omixon, GenDx) and 3 software applications: NGSengine, Twin and SeqNext-HLA

B. Cauwelier, S. Vermeire, W. Rosseel, F. Nollet

PP1.2 The immunosuppressive role of the adipokine leptin in multiple myeloma

M. Favreau, K. Venken, E. De Bruyne, E. Van Valckenborgh, K. Maes, K. Vanderkerken, D. Elewaut, E. Menu

PP3.1 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease

G. Fransolet, G. Ehx, J. Somja, L. Delens, M. Hannon, S. Dubois, P. Drion, J. Caers, S. Humblet-Baron, L. Belle, P. Delvenne, Y. Beguin, G. Conteduca, F. Baron

PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

B. Mahadeb, D. Noubouossie, L. Rozen, T. Besse-Hamme, A. Efira, P. Hermans, B. Gulbis, M.A. Azerad, A. Demulder

PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals

S. Buntinx, P. Antoine, B. Bailly, I. Beukinga, D. Bron, V. De Wilde

PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation

M. Tajdar, M. Herpol, C. Orlando, B. De Bisschop, P. Govaert, K. Jochmans

PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS

G. Birgegård, C. Besses, M. Griesshammer, L. Gugliotta, C. Harrison, M. Hamdani, H. Achenbach, J.J. Kiladjian

PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease

G. Ehx, M. Hannon, S. Humblet-Baron, S. Dubois, C. Daulne, P. Drion, E. Willems, S. Servais, Y. Beguin, F. Baron

PP1.5 Epigenetics in chronic lymphocytic leukemia: significance of TET and IDH enzymes expression on prognosis and influence of microenvironment

M. Van Damme, E. Crompot, N. Meuleman, P. Mineur, D. Bron, L. Lagneaux, B. Stamatopoulos

PP1.3 Galectin-1 is involved in osteoclast biology

J. Muller, M. Binsfeld, S. Dubois, G. Carmeliet, Y. Beguin, R. Heusschen, J. Caers

PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice

C. Grégoire, Y. Beguin, M. Hannon, S. Dubois, B. Baudoux, A. Briquet, C. Lechanteur, G. Ehx, F. Baron

PP1.1 Evaluation of Next Generation Sequencing based clonality analysis of TRG gene rearrangements

B. Cauwelier, S. Vermeire, E. Maelbrancke, K. Vanhouteghem, F. Nollet

O.6 Effect of bone marrow-mesenchymal stromal cell derived extracellular vesicles on survival, migration and chemoresistance of Chronic Lymphocytic Leukemia B-cells

E. Crompot, M. Van Damme, K. Pieters, N. Meuleman, D. Bron, P. Mineur, L. Lagneaux, B. Stamatopoulos

O.5 BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis on the risk of cardiovascular events, major molecular response and overall survival

H. Haguet, J. Douxfils, F. Mullier, C. Chatelain, C. Graux, J-M. Dogné

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

R. Heusschen, J. Muller, M. Binsfeld, E. Plougonven, N. Mahli, G. Carmeliet, A. Léonard, F. Baron, M. Cohen-Solal, K. Vanderkerken, Y. Beguin, E. Menu, J. Caers

O.3 IgHV Mutational Status Analysis By Next-Generation Deep Sequencing In Chronic Lymphocytic Leukemia Patients: Prognostic Significance Of Multiple Subclones And Implication For Disease Cell Origin

B. Stamatopoulos, A. Timbs, H. Dreau, R. Clifford, P. Robbe, A. Burns, J. Mason, A. Schuh

O.2 RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response

I. Hofman, M. Van Duin, G. Mulligan, S. Vereecke, E. Geerdens, E. Garelli, C. Mancini, H. Lemmens, M. Delforge, P. Vandenberghe, I. Wlodarska, A. Aspesi, L. Michaux, P. Sonneveld, K. De Keers-maecker

O.1 Infusion of mesenchymal stem cells (MSC) as treatment for steroid refractory acute graft-versus-host study (aGVHD): a multicenter prospective phase II study of the BHS

S. Servais, D. Selleslag, J. Maertens, L. Lechanteur, E. Baudoux, P. Zachée, H. Schouten, L. Noens, P. Lewalle, W. Schroyens, A. Ory, Y. Beguin

PP4.5 Functional in vitro evaluation of T cells generated from minor H antigen-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system

S. Bonte, S. Snauwaert, M. Heemskerk, B. Vandekerckhove, T. Kerre

P1.08 Long-term Survival and Quality of Life Analysis after Autologous Stem Cell Transplantation for Lymphoma

S. Faict, A. De Becker, K. Fostier, F. Trullemans, R. Schots

P1.07 Genetic alterations in MYC-rearranged aggressive B-cell lymphomas: differences between pediatric and adult Burkitt lymphomas

H. Antoine-Poirel

P1.06 Distinguishing leukemic B-lymphoblasts from normal B-cell precursors using cut-off values for expression of CD24, CD38, CD58 and CD66c

B. Depreter, J. Philippé, B. Denys

P1.05 Exosomal miR-146a from multiple myeloma cells regulates cytokine and chemokine secretion in mesenchymal stromal cells

K. De Veirman, J. Wang, S. Xu, X. Leleu, E. Himpe, K. Maes, E. De Bruyne, E. Van Valckenborgh, K. Vanderkerken, E. Menu, I. Van Riet

P1.04 Tumor-associated macrophages induce Multiple Myeloma cell survival and STAT3 activation

N. De Beule, K. De Veirman, K. Maes, E. De Bruyne, E. Menu, R. Schots, K. Vanderkerken, E. Van Valckenborgh

P1.03 Abnormal IGF-binding protein profile in the bone marrow of multiple myeloma patients

L. Bieghs, M. Brohus, I.B. Kristensen, N. Adilgaard, M. Boegsted, H. Johnsen, C. Conover, E. De Bruyne, K. Vanderkerken, M.T. Overgaard, M. Nyegaard

P1.02 Hypercalcemia and osteolytic bone lesions in adult B-cell lymphoblastic leukemia: a rare but potentially life-threatening presentation

N.C. Granacher, L. Rutsaert, Z. Berneman, W. Schroyens, L. Lammertijn, A. Van De Velde, A. Verlinden, A. Gadisseur

P1.01 Development of a CLL-MRD staining protocol without the use of tandem dyes, and comparison with the ERIC 6-Color Protocol

R. Van Bockstaele

PP4.4 A retrospective study of 109 patients with essential thrombocythemia with a focus on the delay in the diagnosis

F. Lurquin, V. Lannoy, J-P. Defour, L. Knoops

PP4.3 Detection and Monitoring of BCR-ABL1 Kinase Domain Mutations by Next Generation Sequencing

P. Vannuffel, B. Cauwelier, P. Mineur, C. De Rop, D. Pranger, F. Nollet

PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

F. Van Obbergh, L. Knoops, Y. Beguin, C. Graux, S. Benghiat, K. Kargar-Samani, D. Bauwens, A. Efira, C. Dubois, C. Springael, L. Montfort, T. Connerotte, A. Delannoy, P. Wallemacq

PP4.1 Mutation frequency of SETBP1, ASXL1 and CSF3R in myeloid malignancies: retrospective analysis of 123 patients

M. Criel, S. Vermeire, B. Cauwelier, F. Nollet

PP3.5 The conundrum of hematocrit measurements on hematopoietic progenitor cell apheresis products: differences between cell counters

S. Gils, H. Devos, B. Cauwelier, I. Vanlaere, S. Roggeman, J. Emmerechts

PP3.4 Incidence of Cryptosporidium after autologous and allogeneic hematopoietic stem cell transplantation

V. Bordon, C. Dhooge, E. Claerebout, S. Casaert, G. Laureys

PP3.3 The ‘EBMT GVHD App’ improves accuracy of graft versus host disease assessment according to NIH criteria compared to standard practice - A proof of concept

H. Schoemans, K. Goris, R. Van Durm, J. Vanhoof, D. Wolff, H. Greinix, S. Pavletic, S. Lee, J. Maertens, S. De Geest, F. Dobbels, R. Duarte